Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8+ T cells with detection by ELISPOT and HLA-multimer staining

被引:0
作者
Lindsey Chudley
Katy J. McCann
Adam Coleman
Angelica M. Cazaly
Nicole Bidmon
Cedrik M. Britten
Sjoerd H. van der Burg
Cecile Gouttefangeas
Camilla Jandus
Karoline Laske
Dominik Maurer
Pedro Romero
Helene Schröder
Linda F. M. Stynenbosch
Steffen Walter
Marij J. P. Welters
Christian H. Ottensmeier
机构
[1] University of Southampton,Cancer Sciences Unit, Faculty of Medicine, Experimental Cancer Medicine Centre, Southampton General Hospital
[2] Johannes-Gutenberg University GmbH,Translational Oncology, University Medical Center
[3] Leiden University Medical Centre,Department of Clinical Oncology
[4] Eberhard-Karls University,Department of Immunology, Institute for Cell Biology
[5] Ludwig Institute for Cancer Research,Translational Tumour Immunology
[6] Immatics Biotechnologies GmbH,Somers Cancer Research Building (Mailpoint 824), Cancer Sciences Unit, Faculty of Medicine, Southampton General Hospital
[7] University of Southampton,undefined
来源
Cancer Immunology, Immunotherapy | 2014年 / 63卷
关键词
T cell; In vitro stimulation; ELISPOT; Multimer; Harmonisation; Inter-laboratory testing;
D O I
暂无
中图分类号
学科分类号
摘要
Ex vivo ELISPOT and multimer staining are well-established tests for the assessment of antigen-specific T cells. Many laboratories are now using a period of in vitro stimulation (IVS) to enhance detection. Here, we report the findings of a multi-centre panel organised by the Association for Cancer Immunotherapy Immunoguiding Program to investigate the impact of IVS protocols on the detection of antigen-specific T cells of varying ex vivo frequency. Five centres performed ELISPOT and multimer staining on centrally prepared PBMCs from 3 donors, both ex vivo and following IVS. A harmonised IVS protocol was designed based on the best-performing protocol(s), which was then evaluated in a second phase on 2 donors by 6 centres. All centres were able to reliably detect antigen-specific T cells of high/intermediate frequency both ex vivo (Phase I) and post-IVS (Phase I and II). The highest frequencies of antigen-specific T cells ex vivo were mirrored in the frequencies following IVS and in the detection rates. However, antigen-specific T cells of a low/undetectable frequency ex vivo were not reproducibly detected post-IVS. Harmonisation of the IVS protocol reduced the inter-laboratory variation observed for ELISPOT and multimer analyses by approximately 20 %. We further demonstrate that results from ELISPOT and multimer staining correlated after (P < 0.0001 and R2 = 0.5113), but not before IVS. In summary, IVS was shown to be a reproducible method that benefitted from method harmonisation.
引用
收藏
页码:1199 / 1211
页数:12
相关论文
共 238 条
[1]  
Boaz MJ(2009)Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents Clin Vaccine Immunol 16 147-155
[2]  
Hayes P(2003)Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop J Autoimmun 21 365-376
[3]  
Tarragona T(2000)Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial J Immunol Methods 244 81-89
[4]  
Seamons L(2009)Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis PLoS ONE 4 e7972-81
[5]  
Cooper A(2005)Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials AIDS Res Hum Retroviruses 21 68-627
[6]  
Birungi J(2010)Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program Cancer Immunol Immunother 59 619-315
[7]  
Kitandwe P(2008)Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI) Cancer Immunol Immunother 57 303-627
[8]  
Semaganda A(2013)Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols Cancer Immunol Immunother 62 615-618
[9]  
Kaleebu P(2010)Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells Cancer Immunol Immunother 59 609-1713
[10]  
Stevens G(2009)Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium Cancer Immunol Immunother 58 1701-302